Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020)

Akebia Therapeutics (AKBA) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $35.1 million in Q1 2020.

• Non-Current Deferred Tax Liability for Q1 2020 came in at $35.1 million, up 806.04% year-over-year; the trailing twelve-month figure through Mar 2020 was $35.1 million (up 806.04% YoY), and the FY2018 annual result was $119.4 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability improved to $35.1 million in Q1 2020 per AKBA's latest filing, from $1.8 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $119.4 million in Q4 2018 and troughed at $1.8 million in Q3 2019.
• A 3-year average of $32.6 million and a median of $3.9 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 806.04% in 2020 and fell as far as 806.04% in 2020.
• A 3-year view of Non-Current Deferred Tax Liability shows it stood at $119.4 million in 2018, then plunged by 98.53% to $1.8 million in 2019, then soared by 1903.42% to $35.1 million in 2020.
• Business Quant data shows AKBA's Non-Current Deferred Tax Liability at $35.1 million in Q1 2020, $1.8 million in Q3 2019, and $3.0 million in Q2 2019.